Lady of justice showing High Court ruling against Novartis and Bayer

High Court ruling against Novartis and Bayer: Implications

Claudia Rubin and Tom Jaggs explore the implications of the High Court ruling against Novartis and Bayer for pharma. High Court ruling against Novartis and...

NHS long-term plan: Growing importance of prevention medicine

“The challenge now is for the NHS to respond to this changing landscape and to focus on preventing as well as treating the conditions...
researchers of new technologies for antimicrobial resistance

Have analytics been relegated to a reporting function?

Have business analytics been pushed to the background? Business information upgraded, smart CRM datasets, the Predictive Analytics silver bullet and other fairy tales.

Is Brexit good news for pharma?

James Burt, Executive Vice President EMENA, Accord Healthcare, asks whether Brexit will in fact present an opportunity for positive change in pharma and healthcare.
painter removing star from EU flag highlighting access to medicine after Brexit

What do NHS changes mean for tech innovation?

Could changes at the top mean fresh opportunities for tech innovation? Read this in the August issue of Pf Magazine.  For some time it has been...

At the heart of it: The vital role of pharmacies in community health

Read this in the August issue of Pf Magazine.  Community pharmacy has a clear role in promoting and supporting the public’s health. There’s an accessible...

Five ways blockchain is impacting healthcare

Blockchain is one of the most talked about technologies at the moment and boasts huge potential to transform how we deliver healthcare and revolutionise...

Brexit: What will it mean for the regulation of medicines?

What are the implications for the movement of medicines from and into the UK, post-brexit? Mark Quick, executive vice president of corporate development at Recipharm, comments on the current situation and the potential implications of the UK exiting the European Union (EU).

The five key areas to drive growth of UK’s pharmaceutical sector

These 5 things are what pharmaceutical companies should be focusing on to maximise their growth in the UK.

The NHS is 70 – Claudia Rubin asks: what’s next?

From birthday teas to big policy, blood donor drives to special 10p coins, the 70th anniversary of the creation of the NHS is getting...

Latest articles

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

IMBRUVICA® misses primary endpoint in pancreatic cancer trial

AbbVie have released an update on the RESOLVE trial of IMBRUVICA® in combination with chemotherapy agents in metastatic pancreatic cancer.  AbbVie, a research-based global biopharmaceutical company,...
Star Europe reports positive client and candidate feedback.

Star Europe’s Amsterdam office off to positive start

Star Europe has reported good feedback in the Netherlands since opening its Amsterdam office in November. Supported by established resources and infrastructure, the team at...
ORKAMBI® for cystic fibrosis

EC approves Vertex’s ORKAMBI® for cystic fibrosis patients

Vertex Pharmaceuticals announces that the European Commission has granted approval of the label extension for ORKAMBI® for cystic fibrosis patients.  The European Commission has granted approval...